Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer’s disease (DIAD). Gantenerumab was associated with serious safety concerns, including a high incidence of brain bleeding and swelling, possibly leading to an early study termination.
Leave A Comment